i2c Pharmaceutical Services

i2c Pharmaceutical Services is a leading independent inhalation product and device development CRO, offering R&D, analytical and clinical services for pharmaceutical and medtech clients globally. Their proprietary Respitab platform, a novel propellant-dispersible tablet for pMDIs, is the focus of an exclusive partnership with Aptar Pharma for worldwide commercialization/licensing. Notable capabilities include gamma scintigraphy, full-cycle inhaled formulation support (pMDI, DPI, nebuliser, nasal spray), small-scale GMP manufacture, and in-house analytical methods. The company has no therapeutics pipeline of its own (development for clients), and is not a public company.